About: Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection
Creator	Martin-Loeches, I Matos, R Rello, J Balasini, C Barahona, D Barcelona, Autonoma Chiche, J Ciber, Enfermedades Lisboa, T Matos, Á Moreno, R Pearse, R Respiratorias, Rhodes, A Silva, E Sprung, C Villabon, M
Source	Medline; PMC
abstract	INTRODUCTION: Early use of corticosteroids in patients affected by pandemic (H1N1)v influenza A infection, although relatively common, remains controversial. METHODS: Prospective, observational, multicenter study from 23 June 2009 through 11 February 2010, reported in the European Society of Intensive Care Medicine (ESICM) H1N1 registry. RESULTS: Two hundred twenty patients admitted to an intensive care unit (ICU) with completed outcome data were analyzed. Invasive mechanical ventilation was used in 155 (70.5%). Sixty-seven (30.5%) of the patients died in ICU and 75 (34.1%) whilst in hospital. One hundred twenty-six (57.3%) patients received corticosteroid therapy on admission to ICU. Patients who received corticosteroids were significantly older and were more likely to have coexisting asthma, chronic obstructive pulmonary disease (COPD), and chronic steroid use. These patients receiving corticosteroids had increased likelihood of developing hospital-acquired pneumonia (HAP) [26.2% versus 13.8%, p < 0.05; odds ratio (OR) 2.2, confidence interval (CI) 1.1–4.5]. Patients who received corticosteroids had significantly higher ICU mortality than patients who did not (46.0% versus 18.1%, p < 0.01; OR 3.8, CI 2.1–7.2). Cox regression analysis adjusted for severity and potential confounding factors identified that early use of corticosteroids was not significantly associated with mortality [hazard ratio (HR) 1.3, 95% CI 0.7–2.4, p = 0.4] but was still associated with an increased rate of HAP (OR 2.2, 95% CI 1.0–4.8, p < 0.05). When only patients developing acute respiratory distress syndrome (ARDS) were analyzed, similar results were observed. CONCLUSIONS: Early use of corticosteroids in patients affected by pandemic (H1N1)v influenza A infection did not result in better outcomes and was associated with increased risk of superinfections.
has issue date	2010-11-24(xsd:dateTime)
bibo:doi	10.1007/s00134-010-2078-z
bibo:pmid	21107529
has license	no-cc
sha1sum (hex)	24ebbe6927c26bac400e18d6056f7000abb510fc
schema:url	https://doi.org/10.1007/s00134-010-2078-z
resource representing a document's title	Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection
has PubMed Central identifier	PMC7079858
has PubMed identifier	21107529
schema:publication	Intensive Care Med
resource representing a document's body	covid:24ebbe6927c26bac400e18d6056f7000abb510fc#body_text
is schema:about of	named entity 'ICU' named entity 'CORTICOSTEROID THERAPY' named entity 'When' named entity 'influenza A' named entity 'PANDEMIC' named entity 'AFFECTED' named entity 'ANALYZED' named entity '2.4' named entity 'INTENSIVE CARE' named entity 'OBSERVED' named entity 'INCREASED RATE' named entity '1.3' named entity 'MORTALITY' named entity 'INTRODUCTION' named entity '2.2' named entity 'DEVELOPING' named entity 'AFFECTED' named entity '0.7' named entity 'MED' named entity 'ADMISSION' named entity 'EARLY' named entity 'INFECTION' named entity 'ORIGINAL' named entity 'CORTICOSTEROIDS' named entity 'PATIENTS' named entity 'SEVERE' named entity 'SIMILAR' named entity 'INFLUENZA A' named entity 'PATIENTS' named entity 'HAP' named entity 'USE OF' named entity '0.05' named entity 'EARLY' named entity '4.8' named entity 'ASSOCIATED WITH' named entity '0.4' named entity 'RATIO' named entity 'USE OF' named entity '283' named entity 'BUT' named entity 'ACUTE RESPIRATORY DISTRESS SYNDROME' named entity 'RESULTS' covid:arg/24ebbe6927c26bac400e18d6056f7000abb510fc named entity 'patients' named entity 'Intensive Care' named entity '2011' named entity '95% CI' named entity 'developing' named entity 'ARDS' named entity 'hazard ratio' named entity 'acute respiratory distress syndrome' named entity 'infection' named entity 'corticosteroid therapy' named entity 'H1N1' named entity 'corticosteroid therapy' named entity 'Windows' named entity 'influenza A virus' named entity 'prednisolone' named entity 'odds ratio' named entity 'ICU' named entity 'COPD' named entity 'homogenized' named entity 'odds ratio' named entity 'randomized controlled study' named entity 'comorbidities'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software